BioSpace News Archive

Today, the U.S. Food and Drug Administration announced it is seeking public comment on a potential change that would require opioid analgesics used in outpatient settings to be dispensed with prepaid mail-back envelopes and that pharmacists provide patient education on safe disposal of opioids.

The report provides a detailed analysis of changing market dynamics, top segments, value chain, key investment pockets, regional scenario, and competitive landscape.

According to the report by Allied Market Research, titled, “Spectrometry Market”. The report provides a detailed analysis of changing market dynamics, top segments, value chain, key investment pockets, regional scenario, and competitive landscape.

The increase in adoption of the internet of medical things (IoMT) in the healthcare industry and rise in adoption of cloud-based medical device security worldwide present new opportunities in the coming years.

Rise in digitization and growing internet penetration across the globe are expected to offer lucrative opportunities in the industry.

Modalis Therapeutics Corporation today announced that six scientific abstracts have been accepted for presentation at the 25th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT), being held in Washington D.C. and virtually, May 16-19, 2022.

Increasing preference toward minimally invasive procedures are some key factors driving market revenue growth.

Increasing prevalence of skin burns, excessive wound exudation and other skin injuries, growing awareness about benefits of dermal regeneration, and rising applications of skin grafting procedures are key factors expected to drive global market growth.

Schrödinger will report its first quarter 2022 financial results on Wednesday, May 4, 2022, after the financial markets close.

Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-lethal complication of stem-cell transplantation for which there is no approved treatment.